Safety and Tolerability of Ubrogepant Within Various Demographic and Clinical Characteristic Subgroups
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This study evaluated the safety and tolerability of ubrogepant across various demographic and clinical characteristic subgroups using data from 2 multicenter, randomized, double-blind, placebo-controlled, single-attack, phase 3 trials in 1938 adults with a history of migraine with or without aura
- Rates of reported treatment-emergent adverse events were comparable within demographic and clinical characteristic subgroups at both 48 hours and 30 days post dose
- The safety and tolerability of ubrogepant are consistent within the various demographic and clinical characteristic subgroups, with no new safety signals identified
Presenting Author
Jessica Ailani, MD
Director Medstar Georgetown Headache Center, Associate Professor Neurology
Department of Neurology, Georgetown University Hospital
Washington D.C., District of Columbia
Jessica Ailani is a Professor of Clinical Neurology, Director of the Georgetown Headache Center, and Vice Co-Chair of Strategic planning Neurology at MedStar Georgetown University Hospital in Washington, DC. Dr. Ailani is a fellow of the American headache society and the American Academy of Neurology. She holds a position on the board as a member at large, is the co-chair of the Practice management group and is on the scientific and Scottsdale program planning committees . She is section editor of Unusual Headache Syndromes for Current Pain and Headache Reports and a reviewer for several professional journals. Dr. Ailani has presented nationally on topics surrounding headache medicine.
Author disclosures
Jessica Ailani, MD: Alder Biopharmaceuticals (Consulting Fees (e.g., advisory boards))
